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Background: Angiotensin converting enzyme (ACE) inhibitor and angiotensin
receptor blocker (ARB) may induce acute kidney injury (AKI). The aim of this study
was to evaluate the role of the resistive index (RI), which reﬂects renal artery
resistance on renal duplex ultrasonography, as a predictor of AKI in chronic kidney
disease (CKD) patients who are prescribed an ACE inhibitor or ARB.
Methods: We screened 105 CKD patients evaluated with renal duplex ultrasono-
graphy from 2008 to 2012. We excluded patients not treated with ACE inhibitor or
ARB and diagnosed with renal artery stenosis. Finally, we retrospectively analyzed
the medical records of 54 patients. AKI was deﬁned as increased serum creatinine
by 430% compared with baseline after starting ACE inhibitor or ARB treatment.
Results: The mean age of the patients was 60.5713.0 years, serum creatinine level was
1.8570.85 mg/dL and 22.2% of the patients had AKI after the use of an ACE inhibitor or
ARB. The RI (P¼0.006) and the percentages of patients with diabetes (P¼0.008) and
using diuretics (P¼0.046) were higher in the AKI group. The area under the receiver
operating characteristics curve for the prediction of AKI was 0.736 (95% conﬁdence
interval¼0.587–0.885, P¼0.013), and RIZ0.80 predicted AKI with 83.3% sensitivity and
61.9% speciﬁcity. In the multivariate analysis, RIZ0.80 was an independent prognostic
factor [Exp (B)¼8.03, 95% conﬁdence interval¼1.14–56.74, P¼0.037] for AKI.
Conclusion: RIZ0.80 on the renal duplex ultrasonography may be a helpful predictor
for AKI in CKD patients who are prescribed an ACE inhibitor or ARB.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Angiotensin converting enzyme (ACE) inhibitor and angio-
tensin II receptor blocker (ARB) slow the rate of decline of
kidney function and prevent cardiovascular disease in chronic
kidney disease (CKD) patients [1]. The Kidney Disease:n Society of Nephrology. Publi
c-nd/4.0/).
al Medicine, Dong-A
usan 602-715, Korea.Improving Global Outcomes (KDIGO) recommend that ACE
inhibitor or ARB should be used in CKD patients with urine
albumin excretion 4300 mg/day, regardless of the presence of
diabetes [2]. Therefore, physicians commonly prescribe ACE
inhibitor and ARB to not only control hypertension but also to
reduce proteinuria. However, ACE inhibitor and ARB cause renal
hypoperfusion and can occasionally induce an episode of acute
kidney injury (AKI), especially when used in patients with
ischemic renovascular disease. However, there are no deﬁnite
predictors of AKI from ACE inhibitor or ARB. Having a predictorshed by Elsevier. This is an open access article under the CC BY-NC-ND
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might be very useful.
Renal duplex ultrasonography is an accurate noninvasive
diagnosis tool to evaluate signiﬁcant renovascular disease in
patients with renal dysfunction [3,4]. The renal resistive index
(RI) by duplex ultrasonography has been found to be a reliable
marker for evaluating the resistance of the renal artery and a
lower RI is associated with less resistance to ﬂow [5,6]. Renal RI
is also a promising tool to assess the risk of AKI in critically ill
patients with severe sepsis [7]. A renal RI40.71 was helpful for
distinguishing acute tubular necrosis from prerenal AKI in one
study. In addition, a renal RI40.80 was a predictor of worsened
renal function and progression to renal replacement in newly
diagnosed CKD patients [8]. However, there are no studies on
whether renal RI by duplex ultrasonography can help predict an
event of AKI caused by an ACE inhibitor and ARB treatments.
The aim of this study was to evaluate the role of RI, which
reﬂects renal artery resistance on color Doppler ultrasonogra-
phy as a predictor of AKI in CKD patients who are prescribed
an ACE inhibitor or ARB.Figure 1. Renal duplex ultrasonography. Findings in patients with
(A) higher resistive index and (B) normal resistive index.Methods
Patient inclusion and data collection
This single center study was conducted from January 2008
to July 2012. We screened 105 CKD patients (Stage 1–5) who
were evaluated with renal duplex ultrasonography. We
included patients aged 420 years who were treated with an
ACE inhibitor or ARB. We excluded patients with a single
kidney, patients with renal replacement therapy, patients
diagnosed with renal artery stenosis, and patients with clinical
evidence of renovascular stenosis.
Finally, we retrospectively analyzed the medical records of
54 patients, including the patients’ characteristics, underlying
disease, laboratory ﬁndings, and medications, such as diure-
tics. We investigated the sex, age, blood pressure, diabetes,
hypertension, ischemic heart disease, cerebrovascular acci-
dents, and peripheral artery disease of the patients. Their
renal function was evaluated by serum creatinine and the
glomerular ﬁltration rate as estimated by the modiﬁed mod-
iﬁcation of diet in renal disease equation (eGFR). We did not
analyze the medical records, which were not related with AKI
caused by an ACE inhibitor or ARB.
Deﬁnition of AKI caused by ACE inhibitor or ARB
We deﬁned AKI caused by an ACE inhibitor or ARB as
showing any one criterion of two diagnosis criteria: (1) increased
serum creatinine by 430% within 1 month after being treated
with an ACE inhibitor or ARB; and (2) slowly increased serum
creatinine within 3 months of 430% without other cause,
rapidly recovered renal function of 430% after stopping ACE
inhibitor or ARB medication and persistently maintained renal
function for 43 months. All AKI patients stopped ACE inhibitor
or ARB medication and took calcium channel blocker.
Renal duplex ultrasonography
The renal duplex ultrasonography was done within 6 months
at the point of checking baseline serum creatinine levels for the
evaluation of renal artery stenosis and renal blood ﬂow. Renalduplex ultrasonography was performed by one radiologist using
a Siemens Sequoia 512 (Siemens Medical Solutions USA,
Issaquah, WA, USA).
The renal RI was calculated as [1–(end diastolic frequency
shift/peak systolic frequency shift)] using Doppler samples
from the segmental and interlobar arteries of the left or right
kidney with the higher main renal artery peak systolic velo-
city. Using a 3-mm Doppler sample, the parenchymal peak
systolic and end diastolic frequency shifts (kHz) of the seg-
mental and interlobar arteries were obtained (Fig. 1). The
RI was evaluated at least three times in the right and left
kidneys. We selected an RI cutoff value of 0.8 because renal RI
40.80 reliably identiﬁed patients at risk for progressive renal
disease in previous study [8].
Statistical analysis
The data are presented as the mean7standard deviation.
Fisher exact test was used to compare categorical data between
Table 1. Characteristics of patients with and without AKI
All patients (n¼ 54) No AKI (n¼ 42) AKI (n¼ 12) P
Sex (male) 38 (70.4) 31 (73.8) 7 (58.3) 0.309
Age (y) 60.5713.0 59.7714.0 63.478.5 0.382
Medical history
DM 31 (57.4) 20 (47.6) 11 (91.7) 0.008
HTN 49 (90.7) 39 (92.9) 10 (83.3) 0.306
IHD 13 (24.1) 9 (21.4) 4 (33.3) 0.453
CVA 11 (20.4) 8 (19.0) 3 (25.0) 0.693
PAD 5 (9.3) 4 (9.5) 1 (8.3) 0.900
Baseline renal function
Creatinine (mg/dL) 1.8570.85 1.8770.83 1.8070.94 0.811
RUP/Cr (g/g) 3.7573.14 3.3273.10 6.1172.52 0.103
eGFR (mL/min/1.73 m2) 45.3720.7 44.3718.6 48.7727.9 0.544
Right kidney size (cm) 10.4371.56 10.4571.72 10.3670.89 0.859
Systemic factor
Hb (g/dL) 11.9472.19 12.0572.30 11.5571.81 0.492
Albumin (g/dL) 3.9470.55 3.9270.55 4.0070.56 0.660
SBP (mmHg) 139.5727.4 137.8728.0 145.5725.4 0.400
DBP (mmHg) 78.6716.0 78.9716.4 77.5715.0 0.788
PP (mmHg) 60.9721.6 58.9722.2 68.0718.1 0.201
Cardiac EF (%) 54.8710.7 54.0711.6 56.678.6 0.554
Medication
ACE inhibitor 4 (7.4) 2 (4.8) 2 (16.7) 0.210
ARB 38 (70.4) 30 (71.4) 8 (66.7) 0.734
ACE inhibitor+ARB 12 (22.2) 10 (23.8) 2 (16.7) 0.714
Diuretics 30 (55.6) 20 (47.6) 10 (83.8) 0.046
RI 0.7870.09 0.7670.09 0.8570.08 0.006
RRT 21 (38.9) 13 (31.0) 8 (66.7) 0.042
Data are expressed as n (%) or mean 7 SD.
ACE inhibitor, angiotensin converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin II receptor blocker; Combination, ACE inhibitor
and ARB combination; Cr, creatinine; CVA, cerebro-vascular accident; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, ejection fraction; eGFR,
glomerular ﬁltration rate estimated by the modiﬁed modiﬁcation of diet in renal disease equation; Hb, hemoglobin; HTN, hypertension; IHD,
ischemic heart disease; PAD, peripheral artery disease; PP, pulse pressure; RI, resistive index; RRT, renal replacement therapy; RUP, random urine
protein; SBP, systolic blood pressure.
Kidney Res Clin Pract 32 (2013) 158–163160the two groups. Comparisons of parametric data according to
AKI and renal RI were analyzed with an independent t test.
The nonparametric Mann–Whitney U test was used to compare
data with a non-normal distribution. The Spearman analysis was
used for the correlations with renal RI. The renal RI cutoff values
for AKI events were determined by the area under the curve
values through a receiver operating characteristics (ROC) curve.
Univariate and multivariate logistic regression analyses were
used to identify factors that affect AKI. The variables included
age, sex, renal RI, and diuretic use. A P value o0.05 was
considered signiﬁcant. All statistical calculations were performed
with SPSS software version 19.0 (IBM Corporation, Armonk, NY,
USA).Results
General patients characteristics
The patient characteristics are summarized in Table 1. Of the
54 patients, 70.4% were male, 57.4% had diabetes, and the mean
age of the patients was 60.5713.0 years. The causes of CKD were
diabetic nephropathy (57.4%), hypertensive nephropathy (20.9%),
glomerulonephritis including lupus nephritits (16.7%), and others
(5.0%). The percentage of CKD Stage 1 was 1.9%, CKD Stage 2
was 18.5%, CKD Stage 3 was 50.0%, CKD Stage 4 was 25.9%, and
CKD Stage 5 was 3.7%. The mean serum creatinine level was
1.8570.85 mg/dL (range, 0.6–4.8 mg/dL), and the follow-up
period was 36.0721.5 months (Table 1). Fifty-two patients
(90.2%) were treated with an ACE inhibitor or ARB for the control
of hypertension, and two patients were treated for the control ofproteinuria. Most patients (70.4%) were treated with ARB, 7.4%
were treated with ACE inhibitor, and 22.2% received combination
therapy with both ACE inhibitor and ARB. Thirty patients were
treated with diuretics such as furosemide (43.3%), torsemide
(10.0%), and spironolactone, hydrochlorothiazide, metolazone, or
two diuretics (36.7%).
Patient characteristics according to AKI
Based on the deﬁnitions, 22.2% of the patients had AKI, 12.9 %
of the patients had AKI after the use of an ACE inhibitor or ARB
within 1 month, and 9.3% of the patients showed slow decline of
renal function and rapidly recovered from AKI after stopping ACE
inhibitor or ARB treatment. The percentages of patients with
diabetes (P¼0.008), renal progression to end-stage renal disease
needing renal replacement therapy (P¼0.042), and diuretic use
(P¼0.046) were higher in the AKI group than in the non-AKI
group. The occurrence of AKI did not differ between patients
with and without combination therapy of an ACE inhibitor and
an ARB or between patients with and without, cardiovascular
disease, including ischemic heart disease. There were no sig-
niﬁcant differences with respect to the age, sex, systolic blood
pressure, diastolic blood pressure, pulse pressure, hemoglobin,
creatinine and albumin levels, and ejection fraction of the
enrolled patients according to AKI status. The AKI group showed
a signiﬁcantly higher renal RI (0.8570.08 vs. 0.7670.09,
P¼0.006) than the non-AKI group. The AKI group showed a
higher renal RI (0.7870.13 vs. 0.7270.09) than the non-AKI
group among patients taking ACE inhibitor or ARB without
diuretics but was not signiﬁcant. The AKI group showed a lower
eGFR decrease for the periods of 24 months (6.9373.44 vs.
Table 2. Characteristics of patients according to resistive index (RI)
value
RIo0.8
(n¼ 28)
RIZ0.8
(n¼ 26)
P
Sex (male) 20 (71.4) 18 (69.2) 1.000
Age (y) 55.25713.55 66.1579.70 0.001
Medical history
DM 9 (32.1) 22 (84.6) <0.001
HTN 26 (92.9) 23 (88.5) 0.663
IHD 3 (10.7) 10 (38.5) 0.026
CVA 5 (17.9) 6 (23.1) 0.741
PAD 1 (3.6) 4 (15.4) 0.184
Baseline renal function
Creatinine (mg/dL) 1.9471.00 1.7670.64 0.458
RUP/Cr (g/g) 3.5173.36 4.2072.81 0.584
eGFR
(mL/min/1.73 m2)
46.7724.0 43.7716.7 0.606
Right kidney
size (cm)
10.2971.25 10.5771.85 0.359
Systemic Factor
Hb (g/dL) 12.4772.37 11.3871.88 0.070
Albumin (g/dL) 3.9870.61 3.8970.50 0.570
SBP (mmHg) 138.3722.7 140.8732.1 0.739
DBP (mmHg) 85.9712.0 70.6716.1 <0.001
PP (mmHg) 52.3718.9 70.1720.7 0.002
Cardiac EF 57.278.7 53.5711.7 0.320
Medication
ACE inhibitor (%) 2(7.1) 2 (7.7) 1.000
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among patients followed-up over 24 months but was not
signiﬁcant.
Patient characteristics according to renal RI
The area under the ROC curve for the prediction of AKI was
0.736 (95% conﬁdence interval¼0.587–0.885, P¼0.013), and a
renal RIZ0.80 predicted AKI with 83.3% sensitivity and 61.9%
speciﬁcity (Fig. 2). Age (r¼0.381, P¼0.004), pulse pressure
(r¼0.451, P¼0.001), and diastolic blood pressure (r¼0.375,
P¼0.005) were signiﬁcantly correlated with the renal RI. The
percentages of patients with diabetes (Po0.001) and ischemic
heart disease (P¼0.026) were higher in the group with a renal
RIZ0.80 than in the group with a renal RIo0.80. Age (P¼
0.001) and pulse pressure (P¼0.002) were higher and the
diastolic blood pressure (Po0.001) was lower in the group
with a renal RIZ0.80 than in the group with a renal RIo0.80
(Table 2).
In the multivariate analysis, a renal RIZ0.80 was an
independent prognostic factor [Exp (B)¼8.03, 95% conﬁdence
interval¼1.14–56.74, P¼0.037) for AKI in patients who were
prescribed ACE inhibitor or ARB (Table 3).ARB 19 (67.9) 19 (73.1) 0.770
ACE inhibitorþARB 7 (25.0) 5 (19.2) 0.747
Diuretics 11 (39.3) 19 (73.1) 0.016
RI 0.7070.05 0.8670.04 <0.001
ESV 0.2670.82 0.287060 0.411
EDV 0.0970.66 0.0470.16 0.009
AKI 2 (7.1) 10 (38.5) 0.008
Data are expressed as n (%) or mean 7 SD.
ACE inhibitor, angiotensin converting enzyme inhibitor; AKI, acute
kidney injury; ARB, angiotensin II receptor blocker; Combination, ACE
inhibitor and ARB combination; Cr, creatinine; CVA, cerebro-vascular
accident; DBP, diastolic blood pressure; DM, diabetes mellitus; EDV, end
diastolic velocity; EF, ejection fraction; eGFR, glomerular ﬁltration rate
estimated by the modiﬁed modiﬁcation of diet in renal disease
equation; ESV, end systolic velocity; Hb, hemoglobin; HTN, hyperten-
sion; IHD, ischemic heart disease; PAD, peripheral artery disease; PP,
pulse pressure; RUP, random urine protein; SBP, systolic blood pressure.Discussion
ACE inhibitor or ARB treatment deﬁnitely induces AKI in
CKD patients under conditions with identiﬁable precipitating
risk factors such as hypovolemia and sepsis [9]. However, ACE
inhibitor or ARB may cause renal hypoperfusion and lead to
AKI in the absence of deﬁnite risk factors in CKD patients with
atherosclerotic renovascular disease. The existence of micro-
vascular renal arteriolar narrowing is possible but not demon-
strable on renal angiography using magnetic resonance
imaging or conventional angiography in CKD patients. The
renal RI on duplex ultrasonography can reﬂect the resistance
of the renal artery and provide information regarding ischemic
nephropathy. Therefore, high renal RI on duplexFigure 2. The receiver-operating characteristics (ROC) curve for the
prediction of acute kidney injury (AKI). The area under the ROC curve
was 0.736 (95% conﬁdence interval¼ 0.587–0.885, P¼ 0.013), and
a renal RIZ0.80 predicted AKI with 83.3% sensitivity and 61.9%
speciﬁcity.
Table 3. Logistic regression analysis for factors that affect AKI
Variable Exp(B) (95% CI) P
Sex, male 1.60 (0.35–7.39) 0.546
Age 0.98 (0.93–1.05) 0.713
RI 8.03 (1.14–56.74) 0.037
Diuretics use 0.37 (0.06–2.25) 0.282
AKI, acute kidney injury; CI, conﬁdence interval; Exp(B), exponentiation
of the B coefﬁcient, which is an odds ratio; RI, resistive index.ultrasonography may indicate narrowed interlobar artery and
segmental artery derived from atherosclerosis. We suspect
that hemodynamic and prerenal mechanisms are related in
AKI patients with high renal RI. First, vasodilatation capacity of
narrowed renal afferent arteriole is impaired and reduced
when ACE inhibitor and/or ARB administration relieve vaso-
constriction of renal efferent arteriole. Second, AKI after ACE
inhibitor and/or ARB administration may be related to prerenal
AKI because AKI is associated with diuretics use in this study.
In this retrospective study, we observed that a renal RIZ0.80
on duplex ultrasonography was a predictor of AKI caused by an
Kidney Res Clin Pract 32 (2013) 158–163162ACE inhibitor or ARB treatment in CKD patients. To the best of
our knowledge, this report is the ﬁrst to show that a renal
RIZ0.80 on duplex ultrasonography may be informative to
predict AKI caused by an ACE inhibitor or ARB. Further
prospective studies are necessary to conﬁrm the role of renal
RI on duplex ultrasonography as a good predictor for AKI
caused by an ACE inhibitor or ARB therapy.
The renal RI on duplex ultrasonography can reﬂect the
degree of renal damage in CKD, and a renal RIZ0.80 reliably
identiﬁes patients at risk for progressive renal disease [8]. The
presence of renovascular disease assessed using renal duplex
sonography was also associated with severe hypertension and
decreased renal function [10,11]. Furthermore, a high renal RI
was associated with an increased risk of subsequent cardio-
vascular disease events and mortality [12–14]. In this study,
the percentage of renal progression to renal replacement was
higher in the AKI group with a higher renal RI. Therefore, the
renal RI on duplex ultrasonography may be helpful for the
prediction of CKD progression. We recommend renal duplex
ultrasonography in place of kidney ultrasonography for the
evaluation of CKD with respect to renal progression, the risk
for cardiovascular disease, and the prediction of AKI caused by
ACE inhibitor or ARB.
Conditions such as signiﬁcant hypotension, a markedly
decreased heart rate, and a perinephric ﬂuid collection can
increase the renal RI [15,16]. The renal RI measurement should
be avoided in the conditions with perinephric hematoma,
systolic blood pressure o90 mmHg or heart rate o50 beats/
minute. Mild edema or slight dehydration not affecting blood
pressure may have a minimal inﬂuence on RI measurements.
Therefore, renal RI may reﬂect well intrarenal vascular resistance
in CKD patients with mild volume derangement. There was no
case with conditions affecting renal RI in this study. We mea-
sured renal RI at the point of AKI development in patients with
AKI. The sequential renal RI measurement was not done after
recovering renal function in this study. However, we suspect that
sequential renal RI may not be changed after recovering renal
function based on high RI of AKI patients meaning ischemic
nephropathy caused by atherosclerosis. Further prospective stu-
dies are necessary to elucidate the sequential change of renal RI
in AKI caused by an ACE inhibitor or ARB.
Vasodilatation of the efferent glomerular arterioles caused
by an ACE inhibitor or ARB results in a decreased intraglomer-
ular pressure and reductions in both GFR and urine albumin
excretion for long-term renoprotection. A reversible reduction
in the serum creatinine level of up to 30% can be regarded as a
physiological response caused by an ACE inhibitor or ARB
treatment. One cohort analysis of elderly diabetic patients
showed an increased ratio of end-stage renal disease after the
use of ACE inhibitor for 3 years or longer [17]. The CHARM
(Candesartan in Heart Failure-Assessment of Reduction in
Mortality and Morbidity) trials also revealed a higher rate of
the doubling of the serum creatinine level in the candesartan-
treated group compared with the placebo-treated group. In
addition, a recent study showed that the cessation of ACE
inhibitor or ARB increased GFR up to 50% of the baseline level
in advanced CKD patients [18]. Our study also showed that the
serum creatinine level was decreased more than 30% after
stopping ACE inhibitor or ARB therapy in ﬁve CKD patients
with a high renal RI. Therefore, whether renal function is
recovering after the cessation of ACE inhibitor or ARB treatment
should be considered when the patient's renal function is
rapidly declining without other precipitating risk factors.One study showed that of 100 CKD patients with reversible
AKI following the discontinuation of ACE inhibitors and/or
ARB, 75% were older than 65 years, 63% older than 70 years,
and 23% older than 80 years old [9]. In this study, the mean age
of the AKI group was not signiﬁcantly higher than that of the
non-AKI group. However, the mean age of patients with a renal
RIZ0.8 was 465 years and signiﬁcantly higher than that of
patients with a renal RIo0.8. Therefore, we suggest that
physicians should use ACE inhibitor and/or ARB with caution,
especially in patients aged 465 years. Patients receiving
diuretics and with diabetes were also at high risk for AKI
caused by an ACE inhibitor and/or ARB in this study. This result
may be explained by a high atherosclerotic risk of diabetes and
the risk of decreased plasma volume caused by diuretics. Our
study also showed that age, higher pulse pressure, lower
diastolic blood pressure, diabetes, and ischemic heart disease
related with atherosclerosis were associated with a higher
renal RI. Therefore, patients with these clinical ﬁndings should
be evaluated with renal duplex ultrasonography.
This study has several limitations. First, the sample size is
small and the study design is retrospective. Second, we measured
an renal RI at one point without sequential renal RI measure-
ment, although there is no case with conditions affecting renal RI
in this study. Despite these limitations, we found that a renal
RIZ0.80 on Doppler ultrasonography could be an indicator of
the possible occurrence of AKI caused by ACE inhibitor or ARB
treatment. In addition, we found that elderly patients, patients
taking diuretics, patients with ischemic heart disease, patients
with diabetes and patients with high pulse pressure and low
diastolic pressure may be at risk of having high renal RI.
In conclusion, a renal RIZ0.80 on Doppler ultrasonography
may be a helpful predictor for AKI in CKD patients who are
prescribed ACE inhibitors or ARBs. In particular, we suggest that
physicians watch for events of AKI in diabetic CKD patients
taking diuretics and with a high renal RI after prescribing an
ACE inhibitor or ARB.Conﬂict of interest
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